Details of the Drug

General Information of Drug (ID: DMU6TG7)

Drug Name
XMT-1592
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Phase 1/2 [1]
Ovarian cancer 2C73 Phase 1/2 [1]
Drug Type
Antibody drug conjugate
Cross-matching ID
TTD ID
DDL79K
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium/phosphate cotransporter 2B (SLC34A2) TTQPZTM NPT2B_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04396340) First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Mersana Therapeutics.